Herve Aloysius

Title: Herve Aloysius: Innovator in Chemotherapeutic Prodrugs

Introduction

Herve Aloysius is a notable inventor based in Newburgh, NY (US). He has made significant contributions to the field of chemotherapeutic agents, particularly in the development of prodrugs activated by prostate-specific antigen. With a total of 2 patents, his work focuses on enhancing the delivery of cancer treatments.

Latest Patents

Aloysius's latest patents include innovative approaches to target-selective chemotherapeutic ester prodrugs. The first patent, titled "Peptide linker and combination for prodrugs activated by prostate-specific antigen," describes a series of PSA-cleavable peptides that improve the delivery of free doxorubicin and other chemotherapeutic agents into the prostate and prostate tumors. The second patent, "Peptide-linked ester prodrugs activated by prostate-specific antigen," reiterates this concept, emphasizing the efficiency of these prodrugs in targeting prostate cancer.

Career Highlights

Herve Aloysius is affiliated with Rutgers, the State University of New Jersey, where he continues to advance research in the field of cancer therapeutics. His work has garnered attention for its potential to improve treatment outcomes for patients with prostate cancer.

Collaborations

Aloysius collaborates with Longqin Hu, contributing to the innovative research environment at Rutgers. Their combined expertise enhances the development of effective cancer treatment strategies.

Conclusion

Herve Aloysius stands out as an inventor dedicated to improving cancer treatment through innovative prodrug technologies. His contributions are paving the way for more effective therapies in the fight against prostate cancer.